James analyst Gary Nachman maintained an Outperform rating on AbbVie stock (NYSE:ABBV) with a $218.00 price target. The ...

The Stargate Project, a $500B initiative focused on artificial intelligence, lifted AI-driven biotech stocks this week while boosting an unlikely winner, Metagenomi (NASDAQ:MGX), which benefitted from ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on ImmunoPrecise Antibodies (IPA – Research ...

Chairman Larry Ellison highlighted the AI's potential in the development of mRNA-based cancer vaccines. Read more here.

During a speech at the White House on Tuesday, Ellison emphasized AI's ability to detect cancer early through blood tests and its crucial role in creating individualized vaccines rapidly. This ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/100.sbqKNnJW.js ...

Also, in news for AbbVie this week, AbCellera has expanded its existing partnership with the company to include the discovery of T-cell engagers (TCE) for oncology applications. Give your business an ...

We came across a bullish thesis on AbCellera Biologics Inc. (ABCL) on Twitter by Jack Prescott. In this article, we will ...

Guggenheim analyst Vamil Divan lowered the firm’s price target on AbbVie (ABBV) to $212 from $221 and keeps a Buy rating on the shares. The ...

AbCellera announced that it has expanded its existing collaboration with AbbVie Inc. to include the discovery of T-cell engagers (TCE) in oncology.